Log in to search using one of your social media accounts:

 

Cubicin RF (Daptomycin Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 21, 2017 Category: Drugs & Pharmacology Source Type: news

Cubicin RF (Daptomycin Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 13, 2017 Category: Drugs & Pharmacology Source Type: news

Antibiotic effective against drug-resistant bacteria in pediatric skin infections
(University of California - San Diego) Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterial scourge that is resistant to most common antibiotics and thus difficult to treat, particularly in children where it commonly causes complicated skin and skin structure infections. In a randomized, controlled clinical trial -- the first of its kind -- a multi-institution research team reports that daptomycin, part of a new class of antibiotics currently approved only for use in adults, is effective and well-tolerated in children. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 16, 2017 Category: Infectious Diseases Source Type: news

Teva Strengthens Injectables Portfolio with the Launch of an Authorized Generic of Cubicin(R) (Daptomycin for Injection) in the United States
JERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the launch of an authorized generic of Cubicin®1 (daptomycin for injection) 500 mg per vial in the United States. Daptomycin... Biopharmaceuticals, Generics, Product Launch Teva Pharmaceutical, Cubicin, daptomycin, Merck (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 15, 2016 Category: Pharmaceuticals Source Type: news

Cubicin (Daptomycin Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 25, 2016 Category: Drugs & Pharmacology Source Type: news

Daptomycin for Treating Gram-Positive Infections in ChildrenDaptomycin for Treating Gram-Positive Infections in Children
Daptomycin may be a safe and effective treatment choice for children and adolescent patients with Gram-positive infections. The Pediatric Infectious Disease Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 12, 2016 Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news

U.S. Supreme Court rejects patent appeal over Cubicin drug
WASHINGTON (Reuters) - The U.S. Supreme Court on Tuesday rejected Cubist Pharmaceuticals Inc's bid to revive four patents for its antibiotic drug Cubicin, paving the way for rival Hospira Inc to introduce a generic version as soon as this year. (Source: Reuters: Health)
Source: Reuters: Health - May 31, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Periprosthetic Joint Infections Controlled by DaptomycinPeriprosthetic Joint Infections Controlled by Daptomycin
This protocol uses daptomycin-impregnated cement combined with systemic daptomycin, to safely and effectively treat periprosthetic joint infections caused by methicillin-resistant Staphylococci. BMC Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2016 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

FDA Drug Safety Communication: Eosinophilic pneumonia associated with the use of Cubicin (daptomycin)
[07-29-2010] The U.S. Food and Drug Administration (FDA) is informing patients and healthcare professionals about the potential for developing eosinophilic pneumonia during treatment with Cubicin (daptomycin), an intravenous antibacterial drug. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 25, 2016 Category: Drugs & Pharmacology Source Type: news

Merck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, issued the following statement regarding the decision of the U.S. Court of Appeals for the Federal Circuit. The decision validated the patent for CUBICIN® (daptomycin for injection) that expires on June 15, 2016, but invalidated four patents with expiration dates in 2019 and 2020. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Steve Cragle, ...
Source: Merck.com - Corporate News - November 12, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Cubicin MSD NYSE:MRK Source Type: news

Why I’m thankful for my daughter’s MRSA
“What time is surgery today?” Ellie, age 12, croaks. She hasn’t opened her eyes yet, but she knows she’s headed to the operating room … again. It may be the fourth surgery this month, maybe the fifth. We don’t know. What we do know is our routine has changed from soccer carpools and homework battles to twice-weekly trips to the operating room, where the orthopedic surgeon will slice open my baby girl’s thigh and attempt to wash out the deadly bacteria accumulating in her right femur and knee joint. We’re trying to learn the new routine and master a new language. The vocabula...
Source: Thrive, Children's Hospital Boston - October 1, 2015 Category: Pediatrics Authors: Lisa Fratt Tags: All posts MRSA PICC line Source Type: news

Daptomycin Safe for Children With Skin InfectionsDaptomycin Safe for Children With Skin Infections
The potent antibiotic shows safety and efficacy for complicated skin infections in children, but safety concerns prevent studies in newborns. Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 19, 2015 Category: Dermatology Tags: Infectious Diseases News Source Type: news

Left-Sided MRSA Endocarditis Successfully Treated with a Combination of Daptomycin and Ceftaroline
Vancomycin is the recommended drug for treating endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA). Daptomycin is not inferior to vancomycin for treating MRSA bacteremia and right-sided endocarditis. There is synergistic activity between daptomycin and ceftaroline. Fifty percent of all cases of bacterial endocarditis are caused by S. aureus, half of which are caused by methicillin-resistant strains (1). A retrospective review of 133 cases of S. aureus endocarditis indicated an overall mortality rate of 38% for left-sided endocarditis in comparison to 17% for right-sided endocarditis (2). (Source: Cli...
Source: Clinical Microbiology Newsletter - March 24, 2015 Category: Microbiology Authors: Claudia D. Jarrin Tejada, Richard P. Wenzel Tags: Case Report Source Type: news

Patent Losses Put a Costly Damper on Merck's Cubist Buy
Just hours after Merck's $8.4 billion acquisition of Cubist Pharmaceuticals was announced, a federal court invalidated most of the patents protecting the Cubist's top-selling antibiotic, Cubicin. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 9, 2014 Category: Pharmaceuticals Source Type: news

Merck Statement Regarding CUBICIN Patent Litigation
Dateline City: KENILWORTH, N.J. Company Reaffirms Transaction To Proceed as Planned; Expected to Close in First Quarter of 2015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the following statement regarding the decision of the U.S. District Court for the District of Delaware. The decision, which upheld the patent for CUBICIN that expires on June 15, 2016 and invalidated four others, is subject to appeal. Language: English Contact: ...
Source: Merck.com - Corporate News - December 9, 2014 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news

Court rules Hospira can launch generic Cubicin in 2016
(Reuters) - Hospira Inc can launch a generic version of Cubist Pharmaceuticals Inc 's leading drug Cubicin as soon as 2016, a federal judge has ruled. (Source: Reuters: Health)
Source: Reuters: Health - December 8, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Cubicin (daptomycin for injection) 500 mg in 10 mL Single Use Vials...
On August 9, Cubist Pharmaceuticals, Inc. announced the recall of certain lots of Cubicin (daptomycin for injection) 500 mg due to the presence of particulate matter. In light of this news,...(PRWeb August 12, 2014)Read the full story at http://www.prweb.com/releases/2014/08/prweb12087103.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 12, 2014 Category: Pharmaceuticals Source Type: news

Nine Lots of IV Antibiotic Recalled (FREE)
By the Editors Nine lots of the intravenous antibacterial Cubicin (daptomycin 500 mg), used for skin … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 11, 2014 Category: Primary Care Source Type: news

CUBICIN (daptomycin for injection) 500 mg in 10 mL Single Use Vials: Recall - Foreign Particulate Matter
Administration of particulate matter poses a potential safety risk to patients such as a thromboembolism or a life-threatening pulmonary embolism. (Source: FDA MedWatch)
Source: FDA MedWatch - August 9, 2014 Category: American Health Source Type: news

Cubicin (daptomycin for injection) 500 mg in 10 mL Single Use Vials: Recall - Presence Of Particulate Matter
The administration of a glass particulate poses a potential safety risk to patients such as a thromboembolism or a life-threatening pulmonary emboli. (Source: FDA MedWatch)
Source: FDA MedWatch - August 8, 2014 Category: American Health Source Type: news

Cubist Pharma recalls some vials of antibiotic Cubicin
(Reuters) - Cubist Pharmaceuticals Inc said it recalled some vials of its antibiotic Cubicin due to the potential presence of glass particles. (Source: Reuters: Health)
Source: Reuters: Health - August 6, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Announces Recall of Cubicin (daptomycin for injection):...
As the FDA announced on April 18, one lot of Cubicin (daptomycin for injection), by Cubist Pharmaceuticals, is recalled due to the presence of particular matter. In light of this news, AttorneyOne, a...(PRWeb April 25, 2014)Read the full story at http://www.prweb.com/releases/2014/04/prweb11795790.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 26, 2014 Category: Pharmaceuticals Source Type: news

Cubist Pharmaceuticals Issues Voluntary Recall Of Cubicin
Cubist Pharmaceuticals announced that it has issued a voluntary recall of one lot of Cubicin (daptomycin for injection) due to the presence of particulate matter, identified specifically as glass particles. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 21, 2014 Category: Pharmaceuticals Source Type: news

CUBICIN (daptomycin for injection) by Cubist Pharmaceuticals: Recall - Presence of Particulate Matter
Potential risk of thromboembolism, pulmonary emboli, phlebitis, mechanical block of the capillaries or arterioles, activation of platelets, subsequent generation of microthrombi, and emboli. (Source: FDA MedWatch)
Source: FDA MedWatch - April 18, 2014 Category: American Health Source Type: news

Study Refines Renal Dosing of Daptomycin for Staph BacteremiaStudy Refines Renal Dosing of Daptomycin for Staph Bacteremia
A new study from Novartis Pharma helps quantify the best daptomycin regimen for patients with renal impairment and Staphylococcus aureus (MRSA) bacteremia. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 15, 2013 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Treatment of Infections Due to Resistant Staphylococcus aureus
This chapter reviews data on the treatment of infections caused by drug-resistant Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This review covers findings reported in the English language medical literature up to January of 2013. Despite the emergence of resistant and multidrug-resistant S. aureus, we have seven effective drugs in clinical use for which little resistance has been observed: vancomycin, quinupristin–dalfopristin, linezolid, tigecycline, telavancin, ceftaroline, and daptomycin. However, vancomycin is less effective for infections with MRSA isolates that have a higher MIC w...
Source: Springer protocols feed by Microbiology - October 6, 2013 Category: Microbiology Source Type: news

Daptomycin in Treating Vancomycin-Resistant Enterococcal UTIDaptomycin in Treating Vancomycin-Resistant Enterococcal UTI
Daptomycin may be a viable therapeutic option in managing vancomycin-resistant enterococcal UTIs. BMC Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 4, 2013 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Glass Bits Force Recall of Daptomycin
(MedPage Today) -- Four lots of the intravenous antibiotic drug daptomycin (Cubicin) have been recalled because of glass particles found in some vials, the FDA and the drug's manufacturer said. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 30, 2013 Category: Primary Care Source Type: news

Cubicin (daptomycin for injection): Recall - Glass Particulate Matter Present in Four Lots
Risk of thromboembolism and pulmonary emboli, some life-threatening. (Source: FDA MedWatch)
Source: FDA MedWatch - August 29, 2013 Category: American Health Source Type: news

Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of Four Lots of Cubicin (Daptomycin for Injection) 500mg in 10ml Single Use Vials Due to Presence of Particulate Matter
Lexington, Mass. – Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling four lots of CUBICIN® (daptomycin for injection) to the user level due to the presence of particulate matter found in a number of vials from these lots. No adverse events have been reported to date in association with a product complaint of vials containing glass particulates. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 29, 2013 Category: Food Science Source Type: news

Daptomycin Use in Infants and ChildrenDaptomycin Use in Infants and Children
How safe and effective is daptomycin in treating resistant Gram-positive infections in infants and children? Pediatric Pharmacotherapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 25, 2013 Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news

U.S. Court Ruling Favors Cubist in Patent Case vs HospiraU.S. Court Ruling Favors Cubist in Patent Case vs Hospira
A U.S. federal court on Monday ruled in favor of Cubist Pharmaceuticals Inc on the interpretation of patent language in a case involving a generic challenge to its lead drug Cubicin (daptomycin injection) by Hospira Inc. Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 21, 2013 Category: Consumer Health News Tags: Pharmacist News Source Type: news

Early Daptomycin Use May Help in MRSA BacteremiaEarly Daptomycin Use May Help in MRSA Bacteremia
Early daptomycin use may improve outcomes in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia when the vancomycin minimal inhibitory concentration (MIC) is above 1 mcg/L. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 13, 2013 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

SMC accepts ceftaroline fosamil (ZinforoT) for restricted use for adults with complicated skin and soft tissue infections
Source: Scottish Medicines Consortium (SMC) Area: Evidence> Drug Specific Reviews The Scottish Medicines Consortium has accepted ceftaroline fosamil (ZinforoT) for restricted use within NHS Scotland in adults with complicated skin and soft tissue infections.   The SMC restriction applies to use in patients with known or suspected meticillin resistant Staphylococcus aureus (MRSA) infection in the following settings:   . For Gram-positive only infections where vancomycin IV is inappropriate/has not been tolerated or treatment modification is required; and daptomycin IV or linezolid IV is normally u...
Source: NeLM - Drug Specific Reviews - January 15, 2013 Category: Drugs & Pharmacology Source Type: news

Daptomycin treats S. aureus bacteremia without nephrotoxicity
NEW YORK (Reuters Health) - Daptomycin, with or without beta-lactams, controls Staphylococcus aureus bacteremia without worsening renal dysfunction, registry data suggest. (Source: Modern Medicine)
Source: Modern Medicine - January 8, 2013 Category: Journals (General) Source Type: news